Longevity Industry Faces Regulatory Challenges Over NMN

The Wall Street Journal reported on the booming longevity industry and the regulatory challenges faced by companies marketing NMN supplements. The article highlights the dispute between supplement companies and pharmaceutical firms over NMN’s classification and the FDA’s stance on its legality as a dietary supplement.

Court Grants Joint Motion to Stay NMN Lawsuit

A federal court granted a joint motion filed by the NPA and FDA to stay proceedings in the NMN lawsuit, pending the FDA’s response to the NPA’s citizen petition. The FDA indicated it would respond to the petition by July 31, 2025, and would not prioritize enforcement actions against NMN supplements in the interim.